SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-036448
Filing Date
2021-07-13
Accepted
2021-07-13 16:18:48
Documents
65
Period of Report
2021-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-10q_20210531.htm 10-Q 2792194
2 EX-31.1 nrix-ex311_6.htm EX-31.1 19978
3 EX-31.2 nrix-ex312_8.htm EX-31.2 19968
4 EX-32.1 nrix-ex321_7.htm EX-32.1 15639
  Complete submission text file 0001564590-21-036448.txt   8008675

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nrix-20210531.xml EX-101.INS 1574920
6 XBRL TAXONOMY EXTENSION SCHEMA nrix-20210531.xsd EX-101.SCH 50520
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrix-20210531_cal.xml EX-101.CAL 48125
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrix-20210531_def.xml EX-101.DEF 150588
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20210531_lab.xml EX-101.LAB 397188
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20210531_pre.xml EX-101.PRE 294959
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 211088065
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences